{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:39Z","timestamp":1792154559720,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Insys","award":["Study funding"],"award-info":[{"award-number":["Study funding"]}]},{"name":"Insys","award":["technical editorial\/medical writing assistance"],"award-info":[{"award-number":["technical editorial\/medical writing assistance"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,6,5]]},"DOI":"10.1007\/s40263-019-00624-4","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T09:06:31Z","timestamp":1556787991000},"page":"593-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":96,"title":["Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy"],"prefix":"10.1007","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct02324673","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"James W.","family":"Wheless","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Dlugos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Alexander","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Ben","family":"Renfroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isra","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Sparagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-8053","authenticated-orcid":false,"given":"Maria Roberta","family":"Cilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the INS011-14-029 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"issue":"2","key":"624_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1542\/peds.2010-1371","volume":"129","author":"SA Russ","year":"2012","unstructured":"Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics. 2012;129(2):256\u201364.","journal-title":"Pediatrics."},{"key":"624_CR2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/NDT.S115996","volume":"13","author":"AP Ostendorf","year":"2017","unstructured":"Ostendorf AP, Ng YT. Treatment-resistant Lennox\u2013Gastaut syndrome: therapeutic trends, challenges and future directions. Neuropsychiatr Dis Treat. 2017;13:1131\u201340.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"3","key":"624_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551\u201363.","journal-title":"Epilepsia."},{"issue":"5","key":"624_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314\u20139.","journal-title":"N Engl J Med."},{"issue":"3","key":"624_CR5","first-page":"176","volume":"22","author":"CT Campbell","year":"2017","unstructured":"Campbell CT, Phillips MS, Manasco K. Cannabinoids in pediatrics. J Pediatr Pharmacol Ther. 2017;22(3):176\u201385.","journal-title":"J Pediatr Pharmacol Ther."},{"key":"624_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","volume":"75","author":"LR Vilela","year":"2017","unstructured":"Vilela LR, Lima IV, Kunsch EB, et al. Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels. Epilepsy Behav. 2017;75:29\u201335.","journal-title":"Epilepsy Behav."},{"issue":"5","key":"624_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","volume":"150","author":"A Thomas","year":"2007","unstructured":"Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613\u201323.","journal-title":"Br J Pharmacol."},{"issue":"23","key":"624_CR8","doi-asserted-by":"publisher","first-page":"16124","DOI":"10.1074\/jbc.M707104200","volume":"283","author":"HR Ross","year":"2008","unstructured":"Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283(23):16124\u201334.","journal-title":"J Biol Chem."},{"issue":"43","key":"624_CR9","doi-asserted-by":"publisher","first-page":"16546","DOI":"10.1074\/jbc.RA118.004929","volume":"293","author":"MR Ghovanloo","year":"2018","unstructured":"Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018;293(43):16546\u201358.","journal-title":"J Biol Chem."},{"issue":"4","key":"624_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","volume":"134","author":"T Bisogno","year":"2001","unstructured":"Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134(4):845\u201352.","journal-title":"Br J Pharmacol."},{"issue":"11","key":"624_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11910-018-0882-y","volume":"18","author":"TE Gaston","year":"2018","unstructured":"Gaston TE, Szaflarski JP. Cannabis for the treatment of epilepsy: an update. Curr Neurol Neurosci Rep. 2018;18(11):73.","journal-title":"Curr Neurol Neurosci Rep."},{"issue":"6","key":"624_CR12","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791\u2013802.","journal-title":"Epilepsia."},{"issue":"5","key":"624_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2017-1818","volume":"140","author":"SS Wong","year":"2017","unstructured":"Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017;140(5):1\u201318.","journal-title":"Pediatrics."},{"issue":"3","key":"624_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270\u20138.","journal-title":"Lancet Neurol."},{"issue":"21","key":"624_CR15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med."},{"key":"624_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","volume":"35","author":"M Tzadok","year":"2016","unstructured":"Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41\u20134.","journal-title":"Seizure."},{"issue":"20","key":"624_CR17","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378(20):1888\u201397.","journal-title":"N Engl J Med."},{"key":"624_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","volume":"86","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131\u20137.","journal-title":"Epilepsy Behav."},{"issue":"10125","key":"624_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox\u2013Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396.","journal-title":"Lancet."},{"key":"624_CR20","unstructured":"US Food and Drug Administration. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. 2018. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm611046.htm. Accessed 2 Jan 2018."},{"issue":"14","key":"624_CR21","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204\u201311.","journal-title":"Neurology."},{"issue":"8","key":"624_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/epi.14477","volume":"59","author":"JP Szaflarski","year":"2018","unstructured":"Szaflarski JP, Bebin EM, Comi AM, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018;59(8):1540\u20138.","journal-title":"Epilepsia."},{"issue":"15\u201316","key":"624_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","volume":"88","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci. 2011;88(15\u201316):730\u20136.","journal-title":"Life Sci."},{"issue":"4","key":"624_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","volume":"28","author":"R Jiang","year":"2013","unstructured":"Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28(4):332\u20138.","journal-title":"Drug Metab Pharmacokinet."},{"issue":"4","key":"624_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"MM Bergamaschi","year":"2011","unstructured":"Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6(4):237\u201349.","journal-title":"Curr Drug Saf."},{"issue":"8","key":"624_CR26","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia."},{"issue":"11","key":"624_CR27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053\u201367.","journal-title":"CNS Drugs."},{"issue":"1","key":"624_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","volume":"33","author":"TT Sands","year":"2018","unstructured":"Sands TT, Rahdari S, Oldham MS, Caminha Nunes E, Tilton N, Cilio MR. Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US. CNS Drugs. 2018;33(1):47\u201360.","journal-title":"CNS Drugs."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00624-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-019-00624-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00624-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:51:35Z","timestamp":1628603495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-019-00624-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6,5]]}},"alternative-id":["624"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00624-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"2 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study protocol and amendments were approved by an institutional review board\/ethics committee at each participating study center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients and\/or parent(s)\/caregiver(s) provided written informed consent and assent (as applicable) at enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"This study was supported by INSYS Development Company, Inc. Support for technical editorial and medical writing assistance was provided by INSYS Development Company, Inc. Support for Open Access for this publication was provided by INSYS Development Company, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James W. Wheless reports that his institution received research funding from Acadia Pharmaceuticals Inc., GW Pharmaceuticals, plc., INSYS Development Company, Inc., LivaNova, Mallinckrodt, National Institutes of Health, Neurelis, Inc., NeuroPace, Inc., Shainberg Foundation, Upsher-Smith Laboratories, LLC, and Zogenix, Inc.; and has been a consultant and\/or on speaker\u2019s bureaus for CombiMatrix, Eisai Co., Ltd., GW Pharmaceuticals, plc., LivaNova, Lundbeck, Mallinckrodt, NeuroPace, Sun Pharmaceutical Industries, Ltd., Supernus Pharmaceuticals, Inc., and Upsher-Smith Laboratories, LLC. Dennis Dlugos reports that he received salary support from the National Institutes of Health, the Commonwealth of Pennsylvania Department of Health, and the Epilepsy Study Consortium, and he also received research program support for pre-study protocol development agreements with Bio-Pharm Solutions Inc., INSYS Development Company, Inc., and UCB, Inc. His institution received research support for clinical trials from INSYS Development Company, Inc. Ian Miller received honoraria and travel support from INSYS Development Company, Inc. and reports that his institution received study funding from INSYS Development Company, Inc. D. Alexander Oh was an employee of INSYS Development Company, Inc. and owns stock options for INSYS Development Company, Inc. Neha Parikh is an employee of INSYS Development Company, Inc. and owns stock options for INSYS Development Company, Inc. Steven Phillips reports that his institution received study funding from INSYS Development Company, Inc. J. Ben Renfroe reports that his institution received study funding from INSYS Development Company, Inc. Colin M. Roberts reports that his institution received study funding from INSYS Development Company, Inc. Isra Saeed reports that her institution received funding from INSYS Development Company, Inc. Steven P. Sparagana reports that his institution received study funding from INSYS Development Company, Inc. Jin Yu is an employee of INSYS Development Company, Inc. and owns stock options for INSYS Development Company, Inc. Maria Roberta Cilio reports that her institution received research support for clinical trials from INSYS Development Company, Inc; she also has been a consultant for BioMarin Pharmaceutical Inc., GW Pharmaceuticals plc., and Xenon Pharmaceuticals; and she received administrative support paid to her institution and drugs free of charge from GW Pharmaceuticals for previous studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}